HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $16.26 million. The enterprise value is $25.13 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 37.82 million shares outstanding. The number of shares has increased by 2.42% in one year.
| Shares Outstanding | 37.82M |
| Shares Change (YoY) | +2.42% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 47.77% |
| Owned by Institutions (%) | 3.19% |
| Float | 17.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.03 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -146.50 |
Financial Efficiency
Return on equity (ROE) is -344.32% and return on invested capital (ROIC) is -119.52%.
| Return on Equity (ROE) | -344.32% |
| Return on Assets (ROA) | -70.09% |
| Return on Capital (ROIC) | -119.52% |
| Revenue Per Employee | $87,170 |
| Profits Per Employee | -$852,609 |
| Employee Count | 45 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.13% in the last 52 weeks. The beta is 0.84, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -73.13% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 39.77 |
| Average Volume (20 Days) | 30,829 |
Short Selling Information
The latest short interest is 24,886, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 24,886 |
| Short Previous Month | 28,052 |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.14% |
| Short Ratio (days to cover) | 1.06 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $3.92 million and -$38.37 million in losses. Loss per share was -$1.04.
| Revenue | 3.92M |
| Gross Profit | -4.03M |
| Operating Income | -37.18M |
| Pretax Income | -27.39M |
| Net Income | -38.37M |
| EBITDA | -36.58M |
| EBIT | -37.18M |
| Loss Per Share | -$1.04 |
Full Income StatementBalance Sheet
The company has $1.16 million in cash and $10.02 million in debt, giving a net cash position of -$8.86 million or -$0.23 per share.
| Cash & Cash Equivalents | 1.16M |
| Total Debt | 10.02M |
| Net Cash | -8.86M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | -6.30M |
| Book Value Per Share | -0.17 |
| Working Capital | -20.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.95 million and capital expenditures -$4.46 million, giving a free cash flow of -$22.41 million.
| Operating Cash Flow | -17.95M |
| Capital Expenditures | -4.46M |
| Free Cash Flow | -22.41M |
| FCF Per Share | -$0.59 |
Full Cash Flow StatementMargins
| Gross Margin | -102.67% |
| Operating Margin | -947.72% |
| Pretax Margin | -978.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -2,452.46% |